本帖最后由 lkf1002 于 2012-10-27 22:12 编辑
我把重点根据我的理解稍微翻译一下：
2013年在中国进入临床实验，呵呵，谁申请去当小白鼠呀。
MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China
May 7, 2012 11:26 am
中国有个 NovoTek Therapeutics Inc. 的公司跟 加拿大的MaRs 合作
ScarX logoMaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐\\\develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.
这几个合作的组织开发了一种祛除手术后疤痕的药物，然后投入到中国市场。
This project was covered in The Globe and Mail on May 7, 2012.
For many people, developing excessive scar tissue growth after surgery can cause physical discomfort along with emotional and psychological stress. Each year, approximately 240 million surgeries are performed worldwide. Market research suggests an effective anti‐\\\skin‐\\\scarring therapeutic represents a multi-billion dollar opportunity.
Currently, no clinically-proven prescription therapeutic can prevent excessive dermal scarring.
Recognizing this promising treatment’s value and the challenging financing environment for preclinical stage therapeutics, MI initiated a co-development licensing option agreement with NovoTek. Based in Beijing, China, NovoTek will be responsible for development and commercialization costs for the anti‐\\\scarring medication in the Chinese market.
MI and SickKids will receive clinical development milestone payments from NovoTek; MI will also have access to all preclinical and clinical data generated by NovoTek to support future clinical development for strategic markets outside China, including the United States, Canada, Brazil and Korea.
“With a proven track record in clinical development in China and strong ties to the Ontario research community, we believe that NovoTek and its founder, Dr. Jubo Liu, are ideal partners for MaRS Innovation and SickKids to co‐\\\develop, and ultimately commercialize, the anti-scarring therapeutic in the Chinese marketplace and eventually in other territories,” stated Raphael Hofstein, president and CEO of MaRS Innovation.
Dr. Benjamin Alman, head of the Division of Orthopaedic Surgery and senior scientist, Program in Developmental and Stem Cell Biology at SickKids, discovered that a particular molecule known for its analgesic properties could effectively target myofibroblast cells — the cells responsible for producing scar tissue.
Dr. Benjamin Alman 这个药物的发明人，发现了一种特别的分子可以对抗产生疤痕的肌纤维母细胞。
Alman and his team have successfully developed an alternative use for this molecule as an anti‐\\\scarring medication. ScarX, a topical cream containing this molecule, can reduce scarring when applied to a surgical wound, as demonstrated in gold-standard preclinical models.
Alam 已经找到了这个分子的替代品，制成名叫ScarX 的药膏。
Clinical trials are expected to begin in early 2013.
这个药膏在2013年开始临床实验。
“We have a good understanding of which cells are responsible for producing scar tissue during the wound healing process,” says Alman. “The real challenge has been stopping those specific cells from making excessive amounts of scar tissue without negatively impacting the overall wound healing process. This therapeutic cream appears to do exactly that.”
我们都知道在伤口愈合过程中，是什么引起了疤痕，我们真正的挑战来自于是在不影响疤痕缝合的前提下，阻止疤痕的形成。
“NovoTek is thrilled to partner with MI and SickKids to address this unmet clinical need by furthering the development of this anti-scarring product and eventually bringing it to the Chinese marketplace,” says Liu, CEO of NovoTek Therapeutics Inc.
这款产品将进入中国市场。
Alman is the A.J. Latner professor and chair of Orthopaedics at the University of Toronto, vice-chair research of the department of Surgery, and the interim head of the Toronto Musculoskeletal Center. He is also a Canada Research Chair.
|
粤公网安:44030502002385号
发表于 2012-10-27 21:55:18
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
抢沙发
千斤顶
狗仔卡
发表于 2012-10-27 21:58:03
楼主
发表于 2012-10-28 10:39:16
